155 related articles for article (PubMed ID: 15291249)
21. [Pulmonary arterial hypertension in collagen disease: findings of the German Network for Systemic Scleroderma].
Halank M; Seyfarth HJ; Opitz C; Schmeisser A; Ewert R; Höffken G
Dtsch Med Wochenschr; 2007 Feb; 132(7):337; author reply 338. PubMed ID: 17286224
[No Abstract] [Full Text] [Related]
22. Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue.
Ooiwa H; Miyazawa T; Yamanishi Y; Hiyama K; Ishioka S; Yamakido M
Intern Med; 2000 Apr; 39(4):320-3. PubMed ID: 10801148
[TBL] [Abstract][Full Text] [Related]
23. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
Bildirici I; Shumway JB
Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
[TBL] [Abstract][Full Text] [Related]
24. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
Herald N; Laliberte K
Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
[No Abstract] [Full Text] [Related]
25. [Cardio-pulmonary disorders associated with collagen vascular disease].
Mizoguchi H; Matsubara H
Nihon Rinsho; 2009 Mar; 67(3):543-9. PubMed ID: 19280930
[TBL] [Abstract][Full Text] [Related]
26. Continuous intravenous administration of a low dose of epoprostenol greatly decreased serum concentrations of endothelin-1 in primary pulmonary hypertension--a case report.
Kakinuma Y; Honma S; Morimoto T; Maruyama H; Yamazaki A; Ishimitsu T; Yamaguchi I
Angiology; 2005; 56(5):641-5. PubMed ID: 16193207
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary hypertension in older children: new approaches and therapies.
Abman SH
Paediatr Respir Rev; 2006; 7 Suppl 1():S177-9. PubMed ID: 16798555
[No Abstract] [Full Text] [Related]
28. Therapy for primary pulmonary hypertension.
McCormack D
Can Respir J; 2003 Apr; 10(3):169-70. PubMed ID: 12712230
[No Abstract] [Full Text] [Related]
29. [Pulmonary arterial hypertension treated with prostacyclin or calcium blockers].
Andreassen AK; Geiran O; Madsen S; Hognestad A; Simonsen S
Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3393-6. PubMed ID: 14713978
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary hypertension--beyond vasodilator therapy.
Fishman AP
N Engl J Med; 1998 Jan; 338(5):321-2. PubMed ID: 9445414
[No Abstract] [Full Text] [Related]
31. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.
Castro PF; Bourge RC; McGiffin DC; Benza RL; Fan P; Pinkard NB; McGoon MD
Chest; 1998 Jul; 114(1):334-6. PubMed ID: 9674493
[TBL] [Abstract][Full Text] [Related]
32. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
Saji T; Nakayama T; Ishikita T; Matsuura H
Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
[TBL] [Abstract][Full Text] [Related]
33. Understanding pulmonary arterial hypertension.
Holcomb SS
Nursing; 2004 Sep; 34(9):50-4. PubMed ID: 15382383
[No Abstract] [Full Text] [Related]
34. Epoprostenol (prostacyclin) and pulmonary hypertension.
Fishman AP
Ann Intern Med; 2000 Mar; 132(6):500-2. PubMed ID: 10733452
[No Abstract] [Full Text] [Related]
35. Epoprostenol for pulmonary hypertension in scleroderma.
Klings ES; Farber HW
Ann Intern Med; 2000 Jul; 133(2):158. PubMed ID: 10896643
[No Abstract] [Full Text] [Related]
36. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
37. Prostacyclin for secondary pulmonary hypertension.
Kaur K; Brown B; Lombardo F
Ann Intern Med; 2000 Jan; 132(2):165. PubMed ID: 10644284
[No Abstract] [Full Text] [Related]
38. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
[TBL] [Abstract][Full Text] [Related]
39. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
Chin KM; Channick RN; de Lemos JA; Kim NH; Torres F; Rubin LJ
Chest; 2009 Jan; 135(1):130-136. PubMed ID: 18719056
[TBL] [Abstract][Full Text] [Related]
40. [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 1. Pulmonary hypertension associated with connective tissue diseases].
Tanaka S
Nihon Naika Gakkai Zasshi; 2013 Oct; 102(10):2613-20. PubMed ID: 24400542
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
